Viking Therapeutics Inc (VKTX) Quote

Yea this doesn't faze me at all. Brian Lian sold his largest size of shares just BEFORE February 27th data release. If you think selling shares have anything to do with executive conviction after that transaction, you are a clown.

CEO selling tons of shares AGAIN

VKTX stock price was $14.50 a year ago. It would be shocking if insiders weren't selling some.

For my little friend who hates VKTX but knows nothing about clinical trials or science.

Final Rule (42 CFR Part 11) for the Food and Drug Administration Amendments Act of 2007 (FDAAA)
Overview
What is it? U.S. Federal regulation implementing FDAAA 801 effective in 2017
Which clinical trials must follow it? Clinical trials of FDA-regulated drug, biological, or device products other than Phase 1 trials of drug/biological products or small feasibility studies of device products
Does it require registration? Yes
Does it require results submission? Yes

As I said, results from phase I trial data is not required to be reported.

https://clinicaltrials.gov/policy/reporting-requirements#final-rule

The primary completion date for the phase 2 trial of VK2735 weekly sub-cutaneous administration was Feb 27, 2024. VKTX has a year to SUBMIT the data not publish the data.

When must clinical trial results information be submitted for applicable clinical trials subject to §?11.42?

(a)

Standard submission deadline.

In general, for applicable clinical trials subject to §?11.42, clinical trial results information specified in sections 402(j)(3)(C) and 402(j)(3)(I) of the Public Health Service Act (42 U.S.C. 282(j)(3)(C) and 42 U.S.C. 282(j)(3)(I)) or in §?11.48, as applicable, must be submitted no later than 1 year after the primary completion date of the applicable clinical trial.

https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission#p-1440

CEO selling tons of shares AGAIN

By the way, the sub-cutaneous injection of VKTX2735 is given once a week, like Wegovy is. That was the phase II data released at the end of February.

The oral formulation was tested in a phase I trial as a once a month pill. Depending on the dosage used in a phase 2 trial there could be a shorter interval of a smaller dose is used. It is an appetite suppressant not a drug that stops you from eating anything.

Given the “quality” of your commentary I am not surprised you have been suckered by scams in the past.

You are clueless. Companies aren’t required to publish phase I trials and few if any do. You don’t seem to understand what a phase I trial is.

Companies don’t have to publish data for a year.

You are clueless about rules and regulations of the FDA or FDAAA.

sponsors are required to submit certain clinical trials to ClinicalTrials.gov and post results information in accordance with U.S. laws, regulations, and policies. The Food and Drug Administration Amendments Act of 2007 (FDAAA 801) requires sponsors to register certain clinical trials and submit results information to ClinicalTrials.gov.

Transparency of clinical trial information, including through ClinicalTrials.gov, is essential to scientific advancement. Making clinical trial information publicly available fulfills the commitment to volunteer research participants and also enhances public trust.

Oddly Viking posted results in a press release but not on ClinicalTrials.gov - that is a huge red flag.

Viking has never published any research in a peer reviewed journal.

I have had several Biotech scams suspended by the SEC.

A once a month GLP-1 appetite suppressant could be lethal to some. Viking is going to crash and burn.

And Phase 1 results are published - it is complete nonsense to yammer on about the small size of the dataset.

Plus, you can't read a financial statement - Viking doesn't have have $900 million in Cash on Hand.

This is another scam attempting to catch the GLP-1 trend.

IG

👍👍👍

What you don't understand is that short term investments can be impaired. It doesn't mean they have $900 million in assets. That is similar to looking at the Balance Sheet and the Goodwill is listed as $100 million as an Asset - when reading a financial statement I disregard Goodwill and Intangible Assets.

You are grasping at straws. It make me laugh.

Plus, Viking didn't publish the results on ClinicalTrials.gov for Phase 1 and Phase 2. That is a huge red flag.

Thanks for showing us you don't know anything about biotech or publishing in Scientific Journals. First, companies don't usually publish Phase I results as the data set is too small, and phase I trials are usually just about safety and dosage escalation. Second, the phase 2 data for VK2735 was released at the very end of February. It takes several months just to assemble the data and write the manuscript into publication form. Then the manuscript is submitted and reviewers have to be found who have the time and expertise to review the manuscript. Then the reviewers read the manuscript with a fine tooth comb. This can take 1-2 months or in some cases, more. The reviewers provide their comments on the manuscript on and suggestions for writing and data presentation. The manuscript is then sent back to the authors for revisions, well assuming the journal editor thinks it merits publication is. The people who submitted the manuscript make revisions based on reviewer critiques. They can also explain why they disagree with suggestions. Depending on what the reviewers say and what the editor decided, the manuscript can be accepted with the proviso that certain minor changes be made, which might take only a few weeks and not require further input from reviewers are needed. In that case, the manuscript might be published in a month or two more. Alternatively, or a major revision might be required and the manuscript re-reviewed. It isn't uncommon for it to take a year or more until publication.

There is a lack of transparency from Viking.

Nonsense. Again your inexperience in biotech is showing

I generally am skeptical of Short Term Investments.

Feel however you like.

The Viking corporate headquarters is a virtual office - another huge red flag.

Not sure what you are talking about VKTX has 28 full time employees.

...short term investments can be impaired. The “short-term investments” line on a corporate balance sheet usually consists of T-bills or shares of money-market funds. There’s not much chance of these assets being impaired.

Just googled the corporate office location, nice modern building. Parking lot full, obviously alot of tenants. Will try to find research facility.

Besides doing much dd, motley fool did a peice on Viking today. Very good potential pipeline and no need to issue more shares or take out loans.

What you don't understand is that short term investments can be impaired. It doesn't mean they have $900 million in assets. That is similar to looking at the Balance Sheet and the Goodwill is listed as $100 million as an Asset - when reading a financial statement I disregard Goodwill and Intangible Assets.

Plus, Viking didn't publish the results on ClinicalTrials.gov for Phase 1 and Phase 2. That is a huge red flag.

There is a lack of transparency from Viking.

I generally am skeptical of Short Term Investments.

The Viking corporate headquarters is a virtual office - another huge red flag.

IG

You are using - Short-term investments – available-for-sale - that doesn't mean Viking has $900 million in cash on Hand.

The cash and Cash equivalents isn't close to $900.

Deflectors on maximum. They have $900 million in cash and short term investments that can be used to fund the ~$300 million needed for the phase 3 trials. Do you understand what short term investments means? By the way, VKTX won't be spending $300 million on day 1. It will be spread out over 1-2 years. Given the long time frames, that is essentially the same as having cash.

I looked over you posting history. You are an uninformed short whose comments over a wide range of stocks are meaningless. This is just the latest example.

Here is the link for when VKTX raised over $600 million in cash in March of 2024.

https://ir.vikingtherapeutics.com/2024-03-04-Viking-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares

I don't believe you know how to read a financial statement.

You are using - Short-term investments – available-for-sale - that doesn't mean Viking has $900 million in cash on Hand.

The cash and Cash equivalents isn't close to $900.

You might want to look at all of the S-8 which is to register stock to be given to employees as part of a benefit plan. This is dilutive to retail investors.

We already know the insiders are dumping stock.

"Brian Lian - President & CEO of Viking Therapeutics Inc, executed a sale of 35,000 shares in the company on January 30, 2024, according to a recent SEC Filing.

Over the past year, the insider has sold a cumulative total of 349,336 shares of Viking Therapeutics Inc and has not made any purchases of the stock. The company's insider transaction history indicates a pattern of sales with 15 insider sells and no insider buys over the same timeframe.

The transaction was carried out at an average price of $23.95 per share, which resulted in a total value of $837,250. Following this transaction, the insider's stake in Viking Therapeutics Inc has been adjusted as per the latest filings."

IG

Some folks DD is lazy, thanks for setting this $$ record straight!

Where is the capital for the $300 million for Phase 3 clinical trials?

What?? If you have done even the barest minimum of research on VKTX you would know they have over $900 million in cash on hand.

VKTX 2Q24 CC notes by ‘Mufaso’:

#msg-174812392

Where is the capital for the $300 million for Phase 3 clinical trials?

Why hasn't the company posted any of the results from from past studies.

"Results Overview
No Study Results Posted on ClinicalTrials.gov for this Study"

IG

I bet this fine company will be bought out in the next 12months. 👍💰👍💰

$vltx $67's apparently the market likes the news

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
https://seekingalpha.com/article/4706587-viking-therapeutics-better-than-expected-trial-timelines-while-pipeline-expands?mailingid=36182871&messageid=2800&serial=36182871.2121&source=email_2800&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=36182871.2121

TY However, the design of the VK2735 phase-3 trials will not be finalized until after the end-of-phase-2 meeting with the FDA in 2H24, which more than likely means 4Q24.

Viking sends Lilly, Novo lower as obesity drug enters late-stage program

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174804489

$VKTX 62 nhod

$vktx 56 break! $VKTX up 10%+ in AH on a surprise move to Phase 3 trials.

Maybe the best weight loss drug on the planet...and it's Oral vs. Injections for the big winners so far.

Reminder - they did a huge raise at $85 and the stock is currently at $55.

Expecting EPIC call buying tomorrow. https://t.co/LpQIgcoldk— Commodities MacGruber (@GoForGrubes2) July 24, 2024

In since $3.50 sold initial investment at 87.00 riding the houses $

$VKTX

VKTX 10Q due 4/24
Next day settlement begins 5/28

I bet an ELI or NOVO buyout is soon.

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

What a crazy couple of weeks……

Time to jump back in from these levels ??

I think so.

$$ VKTX $$

$VKTX $70'S FROM 79

$vktx $VKTX Truist PT 120

Raymond James PT 115

Irrational selloff

Recall $MDGL irrational selloff I was beating the drum when shares dropped to $168 or so after early data $LLY reported data for MASH

In just few weeks $MDGL actually went higher from selloff pivot point

A $100+…— Pharmdca (@Pharmdca) March 8, 2024

Another marvelous day, fellow Vikings.

Let’s get over $100 already, lol.

$$ VKTX $$

It doesn’t have to own a plant, but it does need a plant that will make its pipeline of molecules better than the Indiana plant of CTLT (NOVO NORDISK) that just got slapped with a warning letter from FDA. I suggested CDMO whose reactor plants have always been FDA approved for good manufacturing methods. Avid Bioservices (CDMO) has supplied raw material to HALO for years to make its Enhanze delivery system for molecules e.g., JNJ’s Darzalex.

Why does VKTX need a proprietary delivery system?

Are you aware of LEXX? Said to have a delivery system for molecules like VKTX has that will turn both into a blockbuster.

I understand that VKTX has no facilities with reactors capable of making its pipeline of molecules. CDMO has an expanded capacity plant up the coast from San Diego in Tustin, and a wholly new plant further up the coast near John Wayne airport. GILD has plants in Forest City, and JNJ has plants in South San Francisco. What do you hear on the topic?

Buying opportunity, imho……

$80 call options look really good to me at this time, imho.

Go Viking!

VKTX sells—(upsized)—7.44M* shares@ $85.00—essentially_no_discount_to_Tuesday’s_closing_price:

https://www.prnewswire.com/news-releases/viking-therapeutics-announces-pricing-of-550-million-public-offering-of-common-stock-302074989.html

Net proceeds will be ~$595M* after underwriting fees.

*Assuming exercising of underwriter’s option.

Another great day…….lets bust through $100 this week.

Oppenheimer adjusts their VKTX price target to $116…….maintains outperform rating.

$$ VKTX $$

If I had this stock at .08, I would be selling.

Didn't ask for much money. This stock will continue to rise.

$1,260,000,000 billion in debt.You need a better pair of glasses—this is VKTX’s 12/31/23 balance sheet:

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001607678/000095017024012322/vktx-20231231.htm#balance_sheets

GILD is providing at least $12 miliion in grant money over 3 years to scores of institutions, states and cities scattered around the country to help women and transgenders to combat HIV. Will this program make Biktarvy available, or will it make VKTX oral/injectable med available, or both. The bigger question is whether GILD will use its remaining cash $$$ to acquire/merge with VKTX, IMO.

Viking Therapeutics proposes $350M stock offering after shares more than double in value

https://www.msn.com/en-us/money/markets/viking-therapeutics-proposes-350m-stock-offering-after-shares-more-than-double-in-value/ar-BB1j0cVc#:~:text=Viking%20Therapeutics%20%28NASDAQ%3AVKTX%29%20on%20Tuesday%20announced%20a%20proposed,trading%20following%20positive%20results%20from%20a%20mid-stage%20trial.

Your debt number is high by a factor of 1,000 and they have hundreds of millions in cash enough for a dozen quarters. And the new offering will double that cash and give them enough cash to make it to market, if they choose.

It's 1.26 million, not billion in debt.

VKTX: And the REAL REASON for this unusual run-up!!! (Brilliantly articulated in the below article!!!)

"MW Viking Therapeutics stock almost doubles as investors cheer cheap entry to weight-loss-drug craze"
https://www.marketwatch.com/story/viking-therapeutics-stock-soars-61-premarket-after-company-reports-positive-results-in-trial-of-weight-loss-drug-50e81767

(I.e., who would have thought that the already 'high' price of VKTX would be viewed as "CHEAP"?? But it indeed is shockingly CHEAP, when compared to the only other two significant PLAYERS in entire 'Weight Loss' science field!!)

It's up 800% in 3 months this is not sustainable. Will blow threw current Cash in like a quarter and is already $1,260,000,000 billion in debt.

Are you new to biotech? VKTX will announce a stock offering in very short order, a day or two, certainly less than a week. It might be 10-15 million at $75/share for $750 million to $1.3 billion in cash so cash flow won't be an issue.